Kamiyacho Neurosurgical Clinic in Japan Celebrates First Brain Tumor Patient Treated with the New ZAP-X® Gyroscopic Radiosurgery® Platform

Novel Setting in Tokyo’s Bustling Business District Looks to Maximize Convenience, Reach New Patients with Potentially Life-Saving Care
Group of physicians gather around ZAP-X, newly installed at the Kamiyacho Neurosurgical Clinic, in Tokyo, Japan

ZAP Surgical, a leading innovator in the field of surgical robotics, today announced the first patient treatment using the groundbreaking ZAP-X® Gyroscopic Radiosurgery® platform at Kamiyacho Neurosurgical Clinic in Tokyo, Japan. The event took place on October 19th, marking a significant milestone in the field of neurosurgical care and cancer treatment. Kamiyacho Neurosurgical Clinic, located on the 2nd floor of the Tokyo World Gate Tower, is the second healthcare facility in Japan to introduce the ZAP-X platform.

The Tokyo World Gate Tower, situated in the vibrant business district of Tokyo, offers an added layer of convenience for patients, not only in the city but for those from all over Japan. The tower’s strategic location is directly connected to the subway station and houses various hotels and company offices.

As a completely non-invasive outpatient treatment for select brain tumors and other cranial indications, stereotactic radiosurgery (SRS) is a proven alternative to historical surgical procedures. Unlike surgery, however, the SRS procedure requires no incisions and is painless. In most cases, patients immediately return to normal activities following SRS.

The ZAP-X system stands out with its innovative design, employing distinct gyroscopic mobility to guide radiosurgical beams from hundreds of unique angles, and ensuring precise radiation concentration on the tumor target. This innovative method aligns with the clinical goal of safeguarding the patient’s healthy brain tissue and maintaining cognitive function.

Additionally, the vault-free ZAP-X system is well-known for its ability to eliminate the high costs associated with constructing shielded radiation treatment rooms. This self-shielding feature successfully cleared the rigorous Japanese nuclear regulations, which are known to be among the most stringent in the world. The ZAP-X also eliminates the necessity of managing, securing, and frequently replacing live radioactive isotopes used in historical radiation beam production.

Combined, these ZAP-X innovations allow for newfound siting flexibility, and consequently bring world-class SRS to locations previously considered infeasible.

Dr. Ryutaro Nomura, Neurosurgeon and Director of Kamiyacho Neurosurgical Clinic, expressed his enthusiasm, stating, “It is impossible to install other radiosurgery devices into such a small clinic in an office building in the Tokyo city center. The ZAP-X’s compact and innovative design has made it possible for us to bring state-of-the-art radiosurgery treatment to our patients in this unique urban outpatient setting.”

Eight additional patients are already booked for ZAP-X treatment later in October, underscoring the clinic’s commitment to offering cutting-edge care to patients across Japan.


About ZAP Surgical Systems, Inc.

ZAP Surgical Systems, Inc. designs and manufactures the ZAP-X® Gyroscopic Radiosurgery® platform. ZAP was founded in 2014 by Dr. John R. Adler. In addition to being CEO of ZAP, Dr. Adler is Emeritus Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University. Dr. Adler is also renowned as the inventor of the CyberKnife® system and founder of Accuray, Inc. The ZAP-X platform incorporates a unique vault-free design that typically eliminates the need for costly shielded treatment rooms. ZAP-X also utilizes a modern linear accelerator to eliminate legacy use of Cobalt-60. Learn more at ZAP Surgical and follow us on LinkedIn.

Contact: Mark Arnold, ZAP Surgical Systems, Inc.
Senior Vice President, Marketing
+1 650 492 7797, ext. 101
Email: info@zapsurgical.com

Recent News

THE ZAP newsletter

Interested in ZAP-X® Gyroscopic Radiosurgery®? Subscribe to our quarterly newsletter for the latest updates, insights and innovations.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.